Free Trial
→ Warning: “DOGE Collapse” imminent (From Altimetry) (Ad) Buy MEDP Stock  Free MEDP Stock Alerts

Medpace (MEDP) Financials

Medpace logo
$282.33 -20.23 (-6.69%)
Closing price 04:00 PM Eastern
Extended Trading
$281.48 -0.85 (-0.30%)
As of 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Medpace

Annual Income Statements for Medpace

This table shows Medpace's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -8.67 13 39 73 100 145 182 245 283 404
Consolidated Net Income / (Loss)		 -8.67 13 39 73 100 145 182 245 283 404
Net Income / (Loss) Continuing Operations		 -8.67 13 39 73 100 145 182 245 283 404
Total Pre-Tax Income 		-7.83 22 57 94 125 169 202 283 336 476
Total Operating Income		 21 52 65 101 127 167 199 279 337 447
Total Gross Profit		 320 371 224 216 861 926 1,142 1,460 1,886 2,109
Total Revenue		 359 422 436 705 861 926 1,142 1,460 1,886 2,109
Operating Revenue		 359 422 436 705 861 926 1,142 1,460 1,886 2,109
Total Cost of Revenue		 39 51 212 489 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 300 318 160 114 734 759 944 1,181 1,549 1,662
Selling, General & Admin Expense		 57 62 63 76 95 92 108 131 161 180
Depreciation Expense		 6.38 7.44 8.57 9.24 8.36 12 16 19 24 28
Amortization Expense		 63 51 38 30 15 7.88 5.11 3.35 2.20 1.44
Other Operating Expenses / (Income)		 164 199 50 - 615 647 814 1,028 1,361 1,453
Total Other Income / (Expense), net		 -28 -31 -7.91 -7.10 -2.43 1.49 3.24 4.16 -1.14 29
Interest & Investment Income		 -27 -19 -7.56 -8.16 -1.57 0.31 -0.11 -2.91 -0.49 25
Other Income / (Expense), net		 -1.13 -0.42 -0.35 1.06 -0.86 1.18 3.34 7.07 -0.66 4.06
Income Tax Expense		 0.84 8.53 18 21 24 23 20 37 53 72
Basic Earnings per Share		 ($0.28) $0.38 $1.00 $2.05 $2.79 $4.07 $5.06 $7.57 $9.20 $13.06
Weighted Average Basic Shares Outstanding		 31.35M 35.69M 39.06M 35.55M 35.88M 35.64M 35.86M 32.39M 30.72M 30.96M
Diluted Earnings per Share		 ($0.28) $0.37 $0.98 $1.97 $2.67 $3.84 $4.81 $7.28 $8.88 $12.63
Weighted Average Diluted Shares Outstanding		 31.35M 36.33M 39.84M 36.91M 37.58M 37.71M 37.70M 33.67M 31.84M 32.01M
Weighted Average Basic & Diluted Shares Outstanding		 31M 35.30M 39.10M 35.70M 36.09M 35.73M 35.23M 31.05M 61.52M 30.47M

Quarterly Income Statements for Medpace

This table shows Medpace's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 66 69 73 61 71 78 103 88 96 117
Consolidated Net Income / (Loss)		 66 69 73 61 71 78 103 88 96 117
Net Income / (Loss) Continuing Operations		 66 69 73 61 71 78 103 88 96 117
Total Pre-Tax Income 		82 74 86 76 83 91 113 110 119 134
Total Operating Income		 78 76 86 78 85 87 104 105 112 125
Total Gross Profit		 384 394 434 461 492 498 511 528 533 537
Total Revenue		 384 394 434 461 492 498 511 528 533 537
Operating Revenue		 384 394 434 461 492 498 511 528 533 537
Total Operating Expenses		 306 318 348 382 408 411 407 423 421 411
Selling, General & Admin Expense		 35 33 38 39 41 43 44 41 49 45
Depreciation Expense		 4.95 5.06 5.41 5.97 6.33 6.42 6.63 6.87 7.16 7.15
Amortization Expense		 0.84 0.84 0.55 0.55 0.55 0.55 0.36 0.36 0.36 0.36
Other Operating Expenses / (Income)		 265 278 304 337 359 362 356 374 364 358
Total Other Income / (Expense), net		 4.07 -2.79 -0.17 -2.65 -1.71 3.39 8.71 5.33 6.50 8.50
Interest & Investment Income		 -1.58 -0.83 -0.86 -1.37 -0.11 1.84 4.12 5.47 7.53 7.88
Other Income / (Expense), net		 5.65 -1.96 0.69 -1.28 -1.60 1.54 4.59 -0.13 -1.03 0.62
Income Tax Expense		 16 4.98 13 15 13 12 10 22 22 17
Basic Earnings per Share		 $2.13 $2.17 $2.35 $2.00 $2.30 $2.55 $3.32 $2.85 $3.11 $3.78
Weighted Average Basic Shares Outstanding		 31.01M 32.39M 31.01M 30.54M 30.63M 30.72M 30.84M 30.99M 31.05M 30.96M
Diluted Earnings per Share		 $2.05 $2.08 $2.27 $1.93 $2.22 $2.46 $3.20 $2.75 $3.01 $3.67
Weighted Average Diluted Shares Outstanding		 32.25M 33.67M 32.16M 31.58M 31.76M 31.84M 32.00M 32.09M 32.09M 32.01M
Weighted Average Basic & Diluted Shares Outstanding		 31.10M 31.05M 30.50M 30.56M 61.37M 61.52M 30.98M 31.00M 31.08M 30.47M

Annual Cash Flow Statements for Medpace

This table details how cash moves in and out of Medpace's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 -38 20 -11 -3.21 109 146 184 -433 217 424
Net Cash From Operating Activities		 86 92 97 157 202 259 263 388 433 609
Net Cash From Continuing Operating Activities		 86 92 97 157 202 259 263 388 433 609
Net Income / (Loss) Continuing Operations		 -8.67 13 39 73 100 145 182 245 283 404
Consolidated Net Income / (Loss)		 -8.67 13 39 73 100 145 182 245 283 404
Depreciation Expense		 6.38 7.44 8.57 9.24 8.36 12 16 19 24 28
Amortization Expense		 66 53 30 22 15 7.17 5.11 3.35 2.20 25
Non-Cash Adjustments To Reconcile Net Income		 41 40 17 44 32 80 104 155 43 -5.13
Changes in Operating Assets and Liabilities, net		 -19 -22 3.09 7.95 46 15 -44 -35 81 157
Net Cash From Investing Activities		 -6.43 -13 -12 -17 -19 -31 -31 -39 -35 -28
Net Cash From Continuing Investing Activities		 -6.43 -13 -12 -17 -19 -31 -31 -39 -35 -28
Purchase of Property, Plant & Equipment		 -6.47 -14 -12 -16 -18 -31 -28 -37 -37 -37
Other Investing Activities, net		 0.03 0.12 0.06 -0.95 -1.23 0.13 -3.09 -1.86 2.02 8.24
Net Cash From Financing Activities		 -116 -58 -98 -142 -74 -82 -44 -776 -183 -154
Net Cash From Continuing Financing Activities		 -116 -58 -98 -142 -74 -82 -44 -776 -183 -154
Repayment of Debt		 -117 -394 -44 -144 -80 0.00 0.00 -274 -155 0.00
Repurchase of Common Equity		 0.00 -2.72 -156 0.00 0.00 -98 -62 -848 -144 -170
Issuance of Debt		 0.00 165 100 - - 0.00 0.00 324 105 0.00
Other Financing Activities, net		 0.25 0.56 1.81 2.49 6.52 16 18 22 11 16
Effect of Exchange Rate Changes		 -0.60 - - - -0.17 - - - 1.08 -2.51
Cash Interest Paid		 24 17 6.89 7.59 1.49 0.10 0.12 2.94 3.06 0.17
Cash Income Taxes Paid		 11 18 17 23 13 23 56 50 76 84

Quarterly Cash Flow Statements for Medpace

This table details how cash moves in and out of Medpace's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -12 -2.74 19 -7.78 56 150 162 104 146 13
Net Cash From Operating Activities		 108 137 80 83 114 156 153 116 149 191
Net Cash From Continuing Operating Activities		 108 137 80 83 114 156 153 116 149 191
Net Income / (Loss) Continuing Operations		 66 69 73 61 71 78 103 88 96 117
Consolidated Net Income / (Loss)		 66 69 73 61 71 78 103 88 96 117
Depreciation Expense		 4.95 5.06 5.41 5.97 6.33 6.42 6.63 6.87 7.16 7.15
Amortization Expense		 0.84 0.84 0.55 0.55 0.55 0.55 0.36 0.36 18 6.18
Non-Cash Adjustments To Reconcile Net Income		 16 64 8.74 10 12 12 63 20 -70 -18
Changes in Operating Assets and Liabilities, net		 21 -2.19 -7.52 4.57 25 59 -20 0.44 97 79
Net Cash From Investing Activities		 -7.19 -9.22 -9.50 -8.47 -8.66 -8.00 2.53 -13 -10 -7.56
Net Cash From Continuing Investing Activities		 -7.19 -9.22 -9.50 -8.47 -8.66 -8.00 2.53 -13 -10 -7.56
Purchase of Property, Plant & Equipment		 -7.18 -9.24 -9.51 -8.45 -8.70 -9.99 -5.50 -13 -11 -7.64
Other Investing Activities, net		 -0.01 0.02 0.01 -0.02 0.04 1.99 8.03 0.08 0.05 0.08
Net Cash From Financing Activities		 -109 -131 -53 -82 -49 1.52 7.66 0.67 6.27 -169
Net Cash From Continuing Financing Activities		 -109 -131 -53 -82 -49 1.52 7.66 0.67 6.27 -169
Repurchase of Common Equity		 - -47 -120 -24 - - 0.00 - - -170
Other Financing Activities, net		 0.89 5.76 2.46 1.66 5.73 1.52 7.66 0.67 6.27 1.26
Effect of Exchange Rate Changes		 - - 0.77 0.38 -0.38 0.32 - - - -1.96

Annual Balance Sheets for Medpace

This table presents Medpace's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 984 979 951 1,005 1,143 1,391 1,660 1,352 1,657 2,101
Total Current Assets		 95 133 130 178 317 474 691 334 594 1,029
Cash & Equivalents		 15 37 26 0.00 132 278 461 28 245 669
Accounts Receivable		 65 80 83 0.00 156 161 186 253 298 296
Prepaid Expenses		 12 16 20 21 29 35 43 52 50 63
Plant, Property, & Equipment, net		 38 44 49 38 47 85 93 110 121 124
Total Noncurrent Assets		 852 802 772 52 779 832 876 909 942 948
Goodwill		 661 661 661 0.00 662 662 662 662 662 662
Intangible Assets		 187 136 99 0.00 54 46 41 38 36 34
Noncurrent Deferred & Refundable Income Taxes		 0.16 0.10 6.34 0.00 0.38 0.54 25 48 74 100
Other Noncurrent Operating Assets		 3.93 4.90 5.94 52 62 123 147 160 170 151
Total Liabilities & Shareholders' Equity		 984 979 951 1,005 1,143 1,391 1,660 1,352 1,657 2,101
Total Liabilities		 571 368 447 406 417 585 707 966 1,098 1,275
Total Current Liabilities		 134 169 193 263 343 440 557 803 925 1,105
Accounts Payable		 8.73 11 17 0.00 22 27 26 33 32 33
Accrued Expenses		 20 24 24 0.00 109 134 159 210 293 308
Current Deferred Revenue		 51 66 74 0.00 192 256 345 463 560 711
Other Current Liabilities		 54 55 62 11 19 24 28 48 40 54
Total Noncurrent Liabilities		 437 200 254 63 74 145 150 163 173 171
Noncurrent Deferred & Payable Income Tax Liabilities		 21 12 0.56 3.16 13 14 1.08 1.07 2.40 1.80
Other Noncurrent Operating Liabilities		 7.29 7.97 11 60 16 131 149 162 170 169
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 413 611 504 -32 726 806 953 386 559 826
Total Preferred & Common Equity		 413 611 504 599 726 806 953 386 559 826
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 413 611 504 -32 726 806 953 386 559 826
Common Stock		 439 624 631 0.00 667 696 728 771 803 844
Retained Earnings		 -23 -9.58 -120 -32 68 115 235 -360 -222 8.17
Treasury Stock		 - 0.00 -6.03 0.00 -6.03 -5.58 -5.43 -12 -12 -12
Accumulated Other Comprehensive Income / (Loss)		 -2.56 -3.74 -0.73 0.00 -2.74 -0.13 -4.85 -12 -10 -15

Quarterly Balance Sheets for Medpace

This table presents Medpace's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 1,328 1,396 1,407 1,487 1,796 1,920 2,084
Total Current Assets		 338 368 379 449 745 873 1,033
Cash & Equivalents		 31 47 39 95 407 511 657
Accounts Receivable		 249 258 275 293 279 301 311
Prepaid Expenses		 58 63 65 61 59 61 64
Plant, Property, & Equipment, net		 105 114 115 115 119 122 124
Total Noncurrent Assets		 886 914 913 923 932 925 927
Goodwill		 662 662 662 662 662 662 662
Intangible Assets		 39 37 37 36 35 35 35
Noncurrent Deferred & Refundable Income Taxes		 27 49 52 59 75 75 77
Other Noncurrent Operating Assets		 158 165 162 165 159 152 154
Total Liabilities & Shareholders' Equity		 1,328 1,396 1,407 1,487 1,796 1,920 2,084
Total Liabilities		 979 1,048 1,016 1,016 1,124 1,156 1,203
Total Current Liabilities		 821 882 852 849 957 993 1,041
Accounts Payable		 28 37 34 29 24 27 26
Accrued Expenses		 204 201 232 265 271 293 307
Current Deferred Revenue		 418 466 491 519 617 638 671
Other Current Liabilities		 31 63 41 36 45 35 37
Total Noncurrent Liabilities		 158 167 163 167 168 163 161
Noncurrent Deferred & Payable Income Tax Liabilities		 0.91 1.09 1.10 1.13 2.36 2.29 2.29
Other Noncurrent Operating Liabilities		 157 165 162 166 165 161 159
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 350 347 391 471 672 764 881
Total Preferred & Common Equity		 350 347 391 471 672 764 881
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 350 347 391 471 672 764 881
Common Stock		 760 779 786 796 815 819 837
Retained Earnings		 -380 -408 -371 -300 -119 -31 66
Treasury Stock		 -14 -12 -12 -12 -12 -12 -12
Accumulated Other Comprehensive Income / (Loss)		 -16 -11 -11 -13 -12 -13 -9.18

Annual Metrics and Ratios for Medpace

This table displays calculated financial ratios and metrics derived from Medpace's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 17.41% 3.46% 61.55% 22.19% 7.54% 23.38% 27.80% 29.17% 11.84%
EBITDA Growth		 0.00% 23.05% -8.78% 30.09% 11.90% 24.91% 19.26% 38.12% 17.65% 38.84%
EBIT Growth		 0.00% 167.99% 23.89% 58.30% 23.79% 33.09% 20.05% 41.50% 17.64% 34.14%
NOPAT Growth		 0.00% 122.97% 38.84% 76.65% 30.09% 40.72% 24.17% 35.11% 17.38% 33.80%
Net Income Growth		 0.00% 254.79% 191.41% 87.07% 37.25% 44.74% 25.08% 34.93% 15.26% 42.99%
EPS Growth		 0.00% 232.14% 164.86% 101.02% 35.53% 43.82% 25.26% 51.35% 21.98% 42.23%
Operating Cash Flow Growth		 0.00% 6.83% 6.16% 60.79% 28.92% 28.14% 1.80% 47.36% 11.68% 40.48%
Free Cash Flow Firm Growth		 0.00% 0.00% 20.13% 805.31% -165.24% 151.06% -15.78% 51.06% 16.34% 41.94%
Invested Capital Growth		 0.00% -4.79% -5.25% -94.97% 1,654.81% -17.44% -6.89% -16.98% -23.18% -50.20%
Revenue Q/Q Growth		 0.00% 0.00% 1.03% 12.71% 4.59% 3.32% 4.47% 6.22% 5.85% 1.84%
EBITDA Q/Q Growth		 0.00% 0.00% -9.07% 19.57% 0.22% 11.02% 1.09% 6.37% 4.46% 9.46%
EBIT Q/Q Growth		 0.00% 0.00% 3.10% 17.48% 4.04% 12.66% 0.60% 6.93% 4.47% 8.97%
NOPAT Q/Q Growth		 0.00% 0.00% 11.85% 16.38% 6.16% 17.37% -1.12% 9.95% 1.55% 9.92%
Net Income Q/Q Growth		 0.00% 0.00% 40.68% 18.59% 7.55% 16.93% -0.46% 8.22% 3.52% 10.59%
EPS Q/Q Growth		 0.00% 0.00% 48.48% 17.96% 8.10% 16.72% -0.62% 11.66% 4.47% 10.60%
Operating Cash Flow Q/Q Growth		 0.00% 0.67% -0.42% 7.40% 9.49% 23.11% -11.61% 20.42% 4.77% 5.96%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 501.96% -533.22% 159.70% -40.90% 24.62% 4.43% 8.15%
Invested Capital Q/Q Growth		 0.00% 0.00% -1.69% -94.62% -2.91% -22.70% -1.62% -11.00% -16.56% -30.48%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 89.15% 87.91% 51.45% 30.59% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 25.52% 26.75% 23.58% 18.99% 17.39% 20.20% 19.53% 21.10% 19.22% 23.86%
Operating Margin		 5.73% 12.45% 14.87% 14.34% 14.78% 18.04% 17.39% 19.09% 17.86% 21.19%
EBIT Margin		 5.41% 12.35% 14.79% 14.49% 14.68% 18.17% 17.68% 19.57% 17.83% 21.38%
Profit (Net Income) Margin		 -2.42% 3.18% 8.97% 10.39% 11.67% 15.70% 15.92% 16.81% 15.00% 19.17%
Tax Burden Percent		 110.77% 61.14% 68.70% 77.90% 80.46% 86.26% 90.09% 86.75% 84.25% 84.97%
Interest Burden Percent		 -40.30% 42.17% 88.28% 92.01% 98.76% 100.18% 99.95% 98.98% 99.85% 105.54%
Effective Tax Rate		 0.00% 38.86% 31.30% 22.10% 19.54% 13.74% 9.91% 13.25% 15.75% 15.03%
Return on Invested Capital (ROIC)		 1.79% 4.09% 5.98% 20.67% 30.29% 24.68% 35.10% 53.74% 78.65% 161.71%
ROIC Less NNEP Spread (ROIC-NNEP)		 -4.12% -2.76% 3.09% 16.86% 52.12% 23.98% 34.31% 52.10% 79.51% 156.31%
Return on Net Nonoperating Assets (RNNOA)		 -3.89% -1.47% 1.04% 10.40% -1.35% -5.70% -14.42% -17.10% -18.82% -103.29%
Return on Equity (ROE)		 -2.10% 2.62% 7.02% 31.06% 28.95% 18.98% 20.68% 36.64% 59.83% 58.42%
Cash Return on Invested Capital (CROIC)		 0.00% 8.99% 11.37% 201.53% -148.14% 43.79% 42.23% 72.30% 104.87% 228.74%
Operating Return on Assets (OROA)		 1.97% 5.30% 6.69% 10.44% 11.77% 13.28% 13.24% 18.97% 22.34% 24.00%
Return on Assets (ROA)		 -0.88% 1.37% 4.05% 7.49% 9.35% 11.48% 11.92% 16.29% 18.80% 21.52%
Return on Common Equity (ROCE)		 -2.10% 2.62% 7.02% 31.06% 28.95% 18.98% 20.68% 36.64% 59.83% 58.42%
Return on Equity Simple (ROE_SIMPLE)		 -2.10% 2.20% 7.77% 12.22% 13.83% 18.04% 19.08% 63.50% 50.60% 48.98%
Net Operating Profit after Tax (NOPAT)		 14 32 45 79 102 144 179 242 284 380
NOPAT Margin		 4.01% 7.61% 10.22% 11.17% 11.89% 15.56% 15.66% 16.56% 15.05% 18.00%
Net Nonoperating Expense Percent (NNEP)		 5.91% 6.85% 2.89% 3.81% -21.82% 0.71% 0.79% 1.64% -0.86% 5.40%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 55.40% 50.77% 45.99%
Cost of Revenue to Revenue		 10.85% 12.09% 48.55% 69.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 15.87% 14.59% 14.53% 10.74% 11.06% 9.95% 9.49% 9.00% 8.56% 8.54%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 83.42% 75.46% 36.57% 16.25% 85.22% 81.96% 82.61% 80.91% 82.14% 78.81%
Earnings before Interest and Taxes (EBIT)		 19 52 65 102 126 168 202 286 336 451
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 92 113 103 134 150 187 223 308 362 503
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.41 2.71 0.00 4.17 6.18 8.21 17.10 16.83 12.51
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 317.58 51.38 31.39 0.00 0.00 80.18
Price to Revenue (P/Rev)		 0.00 3.48 3.13 2.67 3.52 5.38 6.85 4.52 4.99 4.90
Price to Earnings (P/E)		 0.00 109.41 34.86 25.75 30.15 34.25 43.01 26.92 33.26 25.54
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.91% 2.87% 3.88% 3.32% 2.92% 2.32% 3.71% 3.01% 3.92%
Enterprise Value to Invested Capital (EV/IC)		 0.00 2.12 2.19 51.71 4.60 8.90 14.97 16.24 29.22 61.86
Enterprise Value to Revenue (EV/Rev)		 0.00 3.85 3.63 2.67 3.42 5.08 6.44 4.54 4.86 4.58
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 14.40 15.41 14.08 19.65 25.14 33.00 21.51 25.27 19.19
Enterprise Value to EBIT (EV/EBIT)		 0.00 31.18 24.58 18.46 23.28 27.95 36.45 23.19 27.25 21.42
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 50.59 35.58 23.94 28.73 32.63 41.14 27.41 32.28 25.43
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 17.70 16.28 12.04 14.57 18.18 27.95 17.08 21.14 15.86
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 23.01 18.70 2.46 0.00 18.39 34.18 20.38 24.21 17.98
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.99 0.31 0.49 0.00 0.06 0.00 0.00 0.13 0.00 0.00
Long-Term Debt to Equity		 0.99 0.29 0.46 0.00 0.06 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.94 0.53 0.34 0.62 -0.03 -0.24 -0.42 -0.33 -0.24 -0.66
Leverage Ratio		 2.38 1.92 1.73 4.15 3.10 1.65 1.73 2.25 3.18 2.71
Compound Leverage Factor		 -0.96 0.81 1.53 3.82 3.06 1.66 1.73 2.23 3.18 2.86
Debt to Total Capital		 49.68% 23.94% 33.02% 0.00% 5.86% 0.00% 0.00% 11.46% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.01% 1.54% 2.19% 0.00% 0.00% 0.00% 0.00% 11.46% 0.00% 0.00%
Long-Term Debt to Total Capital		 49.67% 22.39% 30.82% 0.00% 5.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 50.32% 76.07% 66.98% 100.00% 94.14% 100.00% 100.00% 88.54% 100.00% 100.00%
Debt to EBITDA		 4.45 1.70 2.41 0.00 0.30 0.00 0.00 0.16 0.00 0.00
Net Debt to EBITDA		 4.26 1.37 2.16 0.00 -0.58 0.00 0.00 0.07 0.00 0.00
Long-Term Debt to EBITDA		 4.45 1.59 2.25 0.00 0.30 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 28.36 5.99 5.57 0.00 0.44 0.00 0.00 0.21 0.00 0.00
Net Debt to NOPAT		 27.13 4.82 4.98 0.00 -0.85 0.00 0.00 0.09 0.00 0.00
Long-Term Debt to NOPAT		 28.36 5.60 5.20 0.00 0.44 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 2.94 2.26 3.68 5.53 6.32 8.02 5.09 6.52 6.53
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.71 0.79 0.67 0.68 0.92 1.08 1.24 0.42 0.64 0.93
Quick Ratio		 0.60 0.69 0.57 0.00 0.84 1.00 1.16 0.35 0.59 0.87
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 71 85 768 -501 256 215 325 378 537
Operating Cash Flow to CapEx		 1,328.23% 677.64% 830.65% 977.18% 1,126.99% 825.39% 931.44% 1,052.22% 1,182.53% 1,665.80%
Free Cash Flow to Firm to Interest Expense		 0.00 6.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 8.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 7.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.36 0.43 0.45 0.72 0.80 0.73 0.75 0.97 1.25 1.12
Accounts Receivable Turnover		 5.52 5.82 5.36 0.00 0.00 5.85 6.58 6.64 6.84 7.09
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 9.57 10.37 9.43 16.32 20.28 14.00 12.82 14.38 16.37 17.27
Accounts Payable Turnover		 4.46 5.19 15.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 66.16 62.71 68.14 0.00 0.00 62.41 55.50 54.98 53.40 51.47
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 81.77 70.33 23.77 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -15.61 -7.62 44.37 0.00 0.00 62.41 55.50 54.98 53.40 51.47
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 804 765 725 36 640 528 492 408 314 156
Invested Capital Turnover		 0.45 0.54 0.59 1.85 2.55 1.59 2.24 3.25 5.23 8.98
Increase / (Decrease) in Invested Capital		 0.00 -38 -40 -689 603 -112 -36 -84 -95 -157
Enterprise Value (EV)		 0.00 1,624 1,585 1,885 2,942 4,702 7,361 6,628 9,160 9,657
Market Capitalization		 0.00 1,469 1,364 1,885 3,029 4,979 7,822 6,606 9,405 10,326
Book Value per Share		 $13.19 $15.00 $13.39 ($0.91) $20.16 $22.53 $26.52 $12.42 $18.22 $26.56
Tangible Book Value per Share		 ($13.85) ($4.58) ($6.81) ($0.91) $0.26 $2.71 $6.93 ($10.10) ($4.54) $4.14
Total Capital		 822 803 752 -32 771 806 953 436 559 826
Total Debt		 408 192 248 0.00 45 0.00 0.00 50 0.00 0.00
Total Long-Term Debt		 408 180 232 0.00 45 0.00 0.00 0.00 0.00 0.00
Net Debt		 390 155 222 0.00 -87 -278 -461 22 -245 -669
Capital Expenditures (CapEx)		 6.47 14 12 16 18 31 28 37 37 37
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -57 -60 -73 -85 -158 -244 -328 -448 -577 -745
Debt-free Net Working Capital (DFNWC)		 -39 -23 -46 -85 -26 34 134 -420 -331 -75
Net Working Capital (NWC)		 -39 -35 -63 -85 -26 34 134 -470 -331 -75
Net Nonoperating Expense (NNE)		 23 19 5.44 5.53 1.96 -1.29 -2.92 -3.61 0.96 -25
Net Nonoperating Obligations (NNO)		 390 155 222 69 -87 -278 -461 22 -245 -669
Total Depreciation and Amortization (D&A)		 72 61 38 32 23 19 21 22 26 52
Debt-free, Cash-free Net Working Capital to Revenue		 -15.87% -14.32% -16.67% -12.12% -18.34% -26.38% -28.68% -30.67% -30.58% -35.31%
Debt-free Net Working Capital to Revenue		 -10.93% -5.45% -10.60% -12.12% -3.02% 3.62% 11.70% -28.73% -17.57% -3.57%
Net Working Capital to Revenue		 -10.94% -8.39% -14.38% -12.12% -3.02% 3.62% 11.70% -32.16% -17.57% -3.57%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.38 $1.00 $2.05 $2.79 $4.07 $5.06 $7.57 $9.20 $13.06
Adjusted Weighted Average Basic Shares Outstanding		 0.00 35.69M 39.06M 35.55M 35.88M 35.64M 35.86M 32.39M 30.72M 30.96M
Adjusted Diluted Earnings per Share		 $0.00 $0.37 $0.98 $1.97 $2.67 $3.84 $4.81 $7.28 $8.88 $12.63
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 36.33M 39.84M 36.91M 37.58M 37.71M 37.70M 33.67M 31.84M 32.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 40.73M 35.48M 35.69M 36.09M 35.73M 35.23M 31.05M 61.52M 30.47M
Normalized Net Operating Profit after Tax (NOPAT)		 21 32 45 79 102 144 179 242 284 380
Normalized NOPAT Margin		 5.82% 7.61% 10.22% 11.17% 11.89% 15.56% 15.66% 16.56% 15.05% 18.00%
Pre Tax Income Margin		 -2.18% 5.21% 13.06% 13.33% 14.50% 18.20% 17.67% 19.37% 17.80% 22.57%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 4.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 2.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 3.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 1.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 20.25% 397.69% 0.00% 0.00% 67.60% 34.15% 345.54% 50.92% 42.01%

Quarterly Metrics and Ratios for Medpace

This table displays calculated financial ratios and metrics derived from Medpace's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 29.83% 27.73% 31.16% 31.22% 28.34% 26.47% 17.73% 14.59% 8.29% 7.66%
EBITDA Growth		 48.91% 29.82% 31.93% 22.82% 1.03% 19.24% 24.56% 34.22% 50.88% 45.38%
EBIT Growth		 52.39% 33.12% 33.13% 23.28% -0.20% 19.32% 25.06% 36.19% 33.54% 41.79%
NOPAT Growth		 31.64% 45.21% 21.21% 31.79% 14.74% 5.76% 29.60% 33.04% 26.60% 45.39%
Net Income Growth		 35.93% 37.25% 18.89% 23.72% 6.85% 14.02% 40.74% 44.68% 36.68% 49.45%
EPS Growth		 58.91% 57.58% 34.32% 32.19% 8.29% 18.27% 40.97% 42.49% 35.59% 49.19%
Operating Cash Flow Growth		 49.95% 92.80% 73.11% -14.59% 5.43% 14.42% 90.67% 41.06% 30.33% 21.91%
Free Cash Flow Firm Growth		 -55.04% 81.08% 0.89% -19.97% 49.10% 9.84% 36.47% 62.46% 56.46% 57.05%
Invested Capital Growth		 -8.23% -16.98% -20.46% -17.02% -18.07% -23.18% -36.31% -37.90% -40.24% -50.20%
Revenue Q/Q Growth		 9.26% 2.70% 10.14% 6.17% 6.86% 1.20% 2.54% 3.34% 0.99% 0.61%
EBITDA Q/Q Growth		 31.09% -9.96% 15.53% -9.93% 7.84% 6.27% 20.68% -2.94% 21.22% 2.39%
EBIT Q/Q Growth		 33.46% -10.79% 16.68% -11.26% 8.04% 6.67% 22.28% -3.35% 5.93% 13.26%
NOPAT Q/Q Growth		 30.85% 13.58% 2.49% -13.47% 13.91% 4.69% 25.59% -11.17% 8.40% 20.23%
Net Income Q/Q Growth		 33.77% 4.00% 6.15% -16.22% 15.53% 10.98% 31.03% -13.88% 9.14% 21.36%
EPS Q/Q Growth		 40.41% 1.46% 9.13% -14.98% 15.03% 10.81% 30.08% -14.06% 9.45% 21.93%
Operating Cash Flow Q/Q Growth		 12.29% 25.99% -41.42% 3.05% 38.62% 36.73% -2.38% -23.76% 28.07% 27.90%
Free Cash Flow Firm Q/Q Growth		 -43.33% 49.00% 16.22% -18.45% 5.58% 9.77% 44.40% -2.92% 1.68% 10.18%
Invested Capital Q/Q Growth		 -6.49% -11.00% 1.77% -2.03% -7.67% -16.56% -15.62% -4.47% -11.15% -30.48%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 23.26% 20.39% 21.39% 18.15% 18.31% 19.23% 22.63% 21.26% 25.51% 25.96%
Operating Margin		 20.28% 19.39% 19.86% 17.01% 17.24% 17.52% 20.36% 19.91% 21.05% 23.37%
EBIT Margin		 21.75% 18.90% 20.02% 16.73% 16.92% 17.83% 21.26% 19.89% 20.86% 23.48%
Profit (Net Income) Margin		 17.21% 17.42% 16.79% 13.25% 14.32% 15.71% 20.07% 16.73% 18.08% 21.81%
Tax Burden Percent		 80.63% 93.24% 84.73% 80.62% 84.79% 86.32% 90.96% 79.97% 81.18% 87.40%
Interest Burden Percent		 98.10% 98.89% 99.01% 98.23% 99.87% 102.08% 103.79% 105.20% 106.77% 106.26%
Effective Tax Rate		 19.37% 6.76% 15.27% 19.38% 15.21% 13.68% 9.04% 20.03% 18.82% 12.60%
Return on Invested Capital (ROIC)		 46.91% 58.69% 56.11% 51.13% 62.43% 79.04% 106.96% 98.00% 117.93% 183.44%
ROIC Less NNEP Spread (ROIC-NNEP)		 44.64% 59.87% 58.11% 49.22% 40.97% 76.43% 102.28% 96.28% 116.52% 181.81%
Return on Net Nonoperating Assets (RNNOA)		 -10.36% -19.65% -0.90% 16.28% 0.67% -18.09% -34.03% -41.28% -64.80% -120.14%
Return on Equity (ROE)		 36.54% 39.04% 55.21% 67.41% 63.11% 60.96% 72.93% 56.73% 53.12% 63.29%
Cash Return on Invested Capital (CROIC)		 54.47% 72.30% 77.09% 78.78% 86.86% 104.87% 134.33% 145.70% 165.47% 228.74%
Operating Return on Assets (OROA)		 20.58% 18.32% 22.84% 20.56% 21.41% 22.35% 26.15% 24.27% 24.20% 26.36%
Return on Assets (ROA)		 16.28% 16.89% 19.16% 16.28% 18.13% 19.69% 24.69% 20.42% 20.97% 24.48%
Return on Common Equity (ROCE)		 36.54% 39.04% 55.21% 67.41% 63.11% 60.96% 72.93% 56.73% 53.12% 63.29%
Return on Equity Simple (ROE_SIMPLE)		 64.80% 0.00% 73.99% 68.70% 58.01% 0.00% 46.54% 44.50% 41.49% 0.00%
Net Operating Profit after Tax (NOPAT)		 63 71 73 63 72 75 95 84 91 110
NOPAT Margin		 16.35% 18.08% 16.83% 13.71% 14.62% 15.12% 18.52% 15.92% 17.09% 20.42%
Net Nonoperating Expense Percent (NNEP)		 2.26% -1.18% -2.00% 1.92% 21.47% 2.61% 4.68% 1.72% 1.40% 1.62%
Return On Investment Capital (ROIC_SIMPLE)		 - 16.33% - - - 13.49% - - - 13.27%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 9.23% 8.48% 8.76% 8.55% 8.41% 8.53% 8.63% 7.85% 9.23% 8.47%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 79.72% 80.61% 80.14% 82.99% 82.76% 82.48% 79.64% 80.09% 78.95% 76.63%
Earnings before Interest and Taxes (EBIT)		 83 74 87 77 83 89 109 105 111 126
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 89 80 93 84 90 96 116 112 136 139
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 13.92 17.10 16.81 18.73 15.71 16.83 18.47 16.71 11.74 12.51
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 193.00 56.14 80.18
Price to Revenue (P/Rev)		 3.54 4.52 3.74 4.38 4.15 4.99 6.32 6.29 5.00 4.90
Price to Earnings (P/E)		 21.49 26.92 22.72 27.26 27.09 33.26 39.68 37.55 28.30 25.54
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 4.65% 3.71% 4.40% 3.67% 3.69% 3.01% 2.52% 2.66% 3.53% 3.92%
Enterprise Value to Invested Capital (EV/IC)		 10.86 16.24 14.22 18.04 19.44 29.22 45.34 48.47 43.16 61.86
Enterprise Value to Revenue (EV/Rev)		 3.62 4.54 3.78 4.39 4.10 4.86 6.11 6.03 4.68 4.58
Enterprise Value to EBITDA (EV/EBITDA)		 17.20 21.51 17.87 21.21 21.05 25.27 31.13 29.59 21.08 19.19
Enterprise Value to EBIT (EV/EBIT)		 18.64 23.19 19.22 22.80 22.70 27.25 33.51 31.75 23.42 21.42
Enterprise Value to NOPAT (EV/NOPAT)		 22.65 27.41 23.21 27.19 26.14 32.28 39.22 37.54 28.06 25.43
Enterprise Value to Operating Cash Flow (EV/OCF)		 15.46 17.08 14.00 18.00 17.66 21.14 23.70 22.69 16.87 15.86
Enterprise Value to Free Cash Flow (EV/FCFF)		 19.08 20.38 16.35 20.77 20.16 24.21 26.27 25.49 19.52 17.98
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.40 0.13 0.33 0.14 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.23 -0.33 -0.02 0.33 0.02 -0.24 -0.33 -0.43 -0.56 -0.66
Leverage Ratio		 2.33 2.25 2.88 4.04 3.43 3.18 3.13 2.88 2.64 2.71
Compound Leverage Factor		 2.28 2.22 2.85 3.97 3.43 3.25 3.25 3.03 2.82 2.88
Debt to Total Capital		 28.53% 11.46% 24.88% 12.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 28.53% 11.46% 24.88% 12.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 71.47% 88.54% 75.12% 87.67% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.48 0.16 0.35 0.16 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.38 0.07 0.21 0.05 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.64 0.21 0.45 0.20 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.49 0.09 0.27 0.06 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.39 4.57 3.82 4.92 5.15 6.03 7.68 7.76 6.37 6.02
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.41 0.42 0.42 0.44 0.53 0.64 0.78 0.88 0.99 0.93
Quick Ratio		 0.34 0.35 0.35 0.37 0.46 0.59 0.72 0.82 0.93 0.87
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 104 155 180 147 155 170 245 238 242 267
Operating Cash Flow to CapEx		 1,511.23% 1,478.78% 841.75% 977.01% 1,314.32% 1,566.14% 2,777.46% 904.34% 1,414.78% 2,494.65%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.95 0.97 1.14 1.23 1.27 1.25 1.23 1.22 1.16 1.12
Accounts Receivable Turnover		 6.31 6.64 6.48 6.68 6.58 6.84 7.31 7.05 6.85 7.09
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 14.29 14.38 14.73 15.32 16.23 16.37 16.89 17.12 17.34 17.27
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 57.82 54.98 56.33 54.63 55.51 53.40 49.92 51.80 53.25 51.47
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 57.82 54.98 56.33 54.63 55.51 53.40 49.92 51.80 53.25 51.47
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 459 408 415 407 376 314 265 253 225 156
Invested Capital Turnover		 2.87 3.25 3.33 3.73 4.27 5.23 5.77 6.16 6.90 8.98
Increase / (Decrease) in Invested Capital		 -41 -84 -107 -83 -83 -95 -151 -154 -151 -157
Enterprise Value (EV)		 4,981 6,628 5,907 7,341 7,305 9,160 11,994 12,250 9,691 9,657
Market Capitalization		 4,872 6,606 5,839 7,325 7,400 9,405 12,401 12,761 10,348 10,326
Book Value per Share		 $11.29 $12.42 $11.18 $12.82 $15.41 $18.22 $21.77 $24.65 $28.43 $26.56
Tangible Book Value per Share		 ($11.33) ($10.10) ($11.36) ($10.11) ($7.45) ($4.54) ($0.85) $2.13 $5.95 $4.14
Total Capital		 490 436 462 446 471 559 672 764 881 826
Total Debt		 140 50 115 55 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 109 22 68 16 -95 -245 -407 -511 -657 -669
Capital Expenditures (CapEx)		 7.18 9.24 9.51 8.45 8.70 9.99 5.50 13 11 7.64
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -374 -448 -446 -458 -495 -577 -619 -631 -666 -745
Debt-free Net Working Capital (DFNWC)		 -343 -420 -399 -419 -400 -331 -212 -121 -8.76 -75
Net Working Capital (NWC)		 -483 -470 -514 -474 -400 -331 -212 -121 -8.76 -75
Net Nonoperating Expense (NNE)		 -3.28 2.60 0.15 2.14 1.45 -2.92 -7.93 -4.26 -5.28 -7.43
Net Nonoperating Obligations (NNO)		 109 22 68 16 -95 -245 -407 -511 -657 -669
Total Depreciation and Amortization (D&A)		 5.79 5.90 5.96 6.52 6.88 6.97 6.99 7.24 25 13
Debt-free, Cash-free Net Working Capital to Revenue		 -27.24% -30.67% -28.54% -27.36% -27.78% -30.58% -31.52% -31.11% -32.14% -35.31%
Debt-free Net Working Capital to Revenue		 -24.99% -28.73% -25.54% -25.02% -22.43% -17.57% -10.79% -5.94% -0.42% -3.57%
Net Working Capital to Revenue		 -35.15% -32.16% -32.90% -28.31% -22.43% -17.57% -10.79% -5.94% -0.42% -3.57%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.13 $2.17 $2.35 $2.00 $2.30 $2.55 $3.32 $2.85 $3.11 $3.78
Adjusted Weighted Average Basic Shares Outstanding		 31.01M 32.39M 31.01M 30.54M 30.63M 30.72M 30.84M 30.99M 31.05M 30.96M
Adjusted Diluted Earnings per Share		 $2.05 $2.08 $2.27 $1.93 $2.22 $2.46 $3.20 $2.75 $3.01 $3.67
Adjusted Weighted Average Diluted Shares Outstanding		 32.25M 33.67M 32.16M 31.58M 31.76M 31.84M 32.00M 32.09M 32.09M 32.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 31.10M 31.05M 30.50M 30.56M 61.37M 61.52M 30.98M 31.00M 31.08M 30.47M
Normalized Net Operating Profit after Tax (NOPAT)		 63 71 73 63 72 75 95 84 91 110
Normalized NOPAT Margin		 16.35% 18.08% 16.83% 13.71% 14.62% 15.12% 18.52% 15.92% 17.09% 20.42%
Pre Tax Income Margin		 21.34% 18.69% 19.82% 16.44% 16.89% 18.20% 22.07% 20.92% 22.27% 24.95%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 353.13% 345.54% 210.95% 71.17% 69.99% 50.92% 7.64% 0.00% 0.00% 42.01%

Frequently Asked Questions About Medpace's Financials

When does Medpace's fiscal year end?

According to the most recent income statement we have on file, Medpace's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Medpace's net income changed over the last 9 years?

Medpace's net income appears to be on an upward trend, with a most recent value of $404.39 million in 2024, falling from -$8.67 million in 2015. The previous period was $282.81 million in 2023.

What is Medpace's operating income?
Medpace's total operating income in 2024 was $446.87 million, based on the following breakdown:
  • Total Gross Profit: $2.11 billion
  • Total Operating Expenses: $1.66 billion
How has Medpace revenue changed over the last 9 years?

Over the last 9 years, Medpace's total revenue changed from $359.06 million in 2015 to $2.11 billion in 2024, a change of 487.4%.

How much debt does Medpace have?

Medpace's total liabilities were at $1.28 billion at the end of 2024, a 16.2% increase from 2023, and a 123.5% increase since 2015.

How much cash does Medpace have?

In the past 9 years, Medpace's cash and equivalents has ranged from $0.00 in 2018 to $669.44 million in 2024, and is currently $669.44 million as of their latest financial filing in 2024.

How has Medpace's book value per share changed over the last 9 years?

Over the last 9 years, Medpace's book value per share changed from 13.19 in 2015 to 26.56 in 2024, a change of 101.4%.

Remove Ads

Related Companies

This page (NASDAQ:MEDP) was last updated on 4/10/2025 by MarketBeat.com Staff
From Our Partners
Trump’s policies mean HUGE income for investors
Thanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...
The Oxford Club | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Feds Just Admitted It—They Can Take Your Cash
The Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...
Priority Gold | Sponsored
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Crypto 101 Media | Sponsored
Elon Musk is helping print “new gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...
True Market Insiders | Sponsored
Three new patents reveal Elon and Trump’s secret “Project America”
Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...
Timothy Sykes | Sponsored
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...
Colonial Metals | Sponsored